[go: up one dir, main page]

NO961046L - Fremgangsmåte for behandling av pasienter med akutt hjerteinfarkt som ikke gjennomgår trombolytisk behandling med hirudin og acetylsalicylsyre - Google Patents

Fremgangsmåte for behandling av pasienter med akutt hjerteinfarkt som ikke gjennomgår trombolytisk behandling med hirudin og acetylsalicylsyre

Info

Publication number
NO961046L
NO961046L NO961046A NO961046A NO961046L NO 961046 L NO961046 L NO 961046L NO 961046 A NO961046 A NO 961046A NO 961046 A NO961046 A NO 961046A NO 961046 L NO961046 L NO 961046L
Authority
NO
Norway
Prior art keywords
hirudin
patients
acetylsalicylic acid
undergo
treatment
Prior art date
Application number
NO961046A
Other languages
English (en)
Norwegian (no)
Other versions
NO961046D0 (no
Inventor
Hubert Dr Heinrichs
Charles H Hennekens
Original Assignee
Behringwerke Ag
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag, Brigham & Womens Hospital filed Critical Behringwerke Ag
Publication of NO961046D0 publication Critical patent/NO961046D0/no
Publication of NO961046L publication Critical patent/NO961046L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO961046A 1995-03-15 1996-03-14 Fremgangsmåte for behandling av pasienter med akutt hjerteinfarkt som ikke gjennomgår trombolytisk behandling med hirudin og acetylsalicylsyre NO961046L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40526995A 1995-03-15 1995-03-15
US44055695A 1995-05-12 1995-05-12

Publications (2)

Publication Number Publication Date
NO961046D0 NO961046D0 (no) 1996-03-14
NO961046L true NO961046L (no) 1996-09-16

Family

ID=27019016

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961046A NO961046L (no) 1995-03-15 1996-03-14 Fremgangsmåte for behandling av pasienter med akutt hjerteinfarkt som ikke gjennomgår trombolytisk behandling med hirudin og acetylsalicylsyre

Country Status (14)

Country Link
EP (1) EP0732102A3 (es)
JP (1) JPH0920681A (es)
KR (1) KR960033468A (es)
CN (1) CN1141809A (es)
AR (1) AR002968A1 (es)
AU (1) AU711660B2 (es)
BR (1) BR9601024A (es)
CA (1) CA2171509A1 (es)
FI (1) FI961171L (es)
IL (1) IL117485A0 (es)
NO (1) NO961046L (es)
NZ (1) NZ286082A (es)
SG (1) SG43242A1 (es)
UY (1) UY24181A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004262776A (ja) * 2003-02-21 2004-09-24 Teikoku Seiyaku Co Ltd 血管新生促進剤
CA2538366A1 (en) * 2003-09-19 2005-03-31 Kissei Pharmaceutical Co., Ltd. Concurrent drugs
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
EA200900091A1 (ru) * 2006-07-17 2009-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний

Also Published As

Publication number Publication date
NZ286082A (en) 1998-09-24
KR960033468A (ko) 1996-10-22
AR002968A1 (es) 1998-05-27
FI961171L (fi) 1996-09-16
AU711660B2 (en) 1999-10-21
NO961046D0 (no) 1996-03-14
EP0732102A3 (en) 1999-01-27
CA2171509A1 (en) 1996-09-16
IL117485A0 (en) 1996-07-23
SG43242A1 (en) 1997-10-17
AU4807296A (en) 1996-09-26
EP0732102A2 (en) 1996-09-18
FI961171A0 (fi) 1996-03-13
CN1141809A (zh) 1997-02-05
JPH0920681A (ja) 1997-01-21
BR9601024A (pt) 1997-12-30
UY24181A1 (es) 1996-03-20

Similar Documents

Publication Publication Date Title
Bodner et al. Efficacy of fibrin sealant in patients on various levels of oral anticoagulant undergoing oral surgery
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
FI922325A0 (fi) Oral sammansaettning foer botning av inflammatoriska tarmkanalsjukdomar.
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
NO972475L (no) Ny antitrombotisk formulering, fremgangsmåte for dens fremstilling og anvendelse derav
UA41398C2 (uk) Спосіб лікування пацієнта і спосіб зниження ризику кровотеч та крововиливів в мозок у хворого, який потребує тромболітичної терапії, фармацевтична комбінація у формі заздалегідь упакованої одиниці і фармацевтична пакувальна одиниця, що складається з цієї комбінації
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
LELCUK et al. Inhibition of ischemia-induced thromboxane synthesis in man
EP0671414A4 (en) ANTITHROMBOTIC.
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
NO961046L (no) Fremgangsmåte for behandling av pasienter med akutt hjerteinfarkt som ikke gjennomgår trombolytisk behandling med hirudin og acetylsalicylsyre
IL163091A (en) Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction
NO934832L (no) Farmasöytisk sammensetning for forhindring eller behandling av arterioscherose
Shulman Heparin and atherosclerosis: an investigative report on the treatment of atherosclerosis
ATE257377T1 (de) Blister enthaltend ein transdermales therapeutisches system und eine einzeldosierte darreichungsform
CA2293913A1 (en) Treatment of necrotizing infections
Brenman Pentoxifylline as adjunctive therapy in leg ulcer management
Harjola et al. The effect of dipyridamole and warfarin on the patency rate of coronary artery bypass grafts
Boldt RETRACTED: Invited letter concerning: Aprotinin use in pediatric cardiac operations: Reply to the Editor
Marder Thrombolytic agents: Balancing cost, efficacy, and side effects
EA199700025A1 (ru) Применение олигосахарида и аспирина для приготовления медикаментов, предназначенных для лечения тромбоэмболических заболеваний, фармацевтическая композиция, способ лечения
Ellis Jr Tissue expansion as an adjunct to reconstruction of congenital and acquired auricular deformities: Chana JS, Grobbelaar AO, Gault DT. Br J Plast Surg 50: 456, 1997
Haug Zidovudine toxicity in uninfected health care workers: Ippolito GM, Puro V. Am J Med 102 (5B): 58, 1997
UA9672A (uk) Спосіб лікування деструктивних форм гострого панкреатиту

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application